US4544551A - Antipeptic ulcer composition - Google Patents

Antipeptic ulcer composition Download PDF

Info

Publication number
US4544551A
US4544551A US06/350,865 US35086582A US4544551A US 4544551 A US4544551 A US 4544551A US 35086582 A US35086582 A US 35086582A US 4544551 A US4544551 A US 4544551A
Authority
US
United States
Prior art keywords
composition
ulcer
weight
clove
antipeptic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/350,865
Inventor
Du Hong-Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HONG YUE DU
Original Assignee
Hong Yue Du
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Yue Du filed Critical Hong Yue Du
Application granted granted Critical
Publication of US4544551A publication Critical patent/US4544551A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/61Myrtaceae (Myrtle family), e.g. teatree or eucalyptus

Definitions

  • the present invention relates to an antipeptic ulcer composition. More particularly, it provides an antipeptic ulcer composition comprising, ferrous sulfate, clove and optionally licorice herebelow referred as agents A, B and C, respectively.
  • the agent A ferrous sulfate
  • the agent B clove
  • the agent C licorice
  • compositions of agents A, B and C have been carrying out research on various compositions of agents A, B and C. It is found no curative effect when merely use agents A and C.
  • a composition using A and B, herebelow referred as CD indeed has some curative effect.
  • a composition using A, B and C herebelow referred as CD1 shows excellent synergistic cooperative action in treating peptic ulcer.
  • the mechanism in the curative action of said compositions CD or CD1 has not been clarified yet, but it seems to be very different from that of antacid or anticholinergic drug.
  • CD1 is much more effective than antacid, antipeptic agent (carrageenin), and anticholinergic drug (atropine sulfate).
  • the curative ratio of CD1 even exceeds that of the most effective drug FM100.
  • the antipeptic ulcer compositions of the present invention CD and CD1 are prepared by compounding agents A, B and A, B, C respectively.
  • compositions of the present invention are administered as antipeptic ulcer compositions, it is advantageous to administer them as tablets, powders capsules or granules.
  • the pharmaceutically acceptable excipients which can be used for said purpose are corn starch, or starch paste.
  • the animal test procedures are like those in acetic acid ulcer (so-called intractible ulcer).
  • the details of the experimental procedures can be obtained with reference to Jap. J. Pharmacology 19.418, 1969 by Takagi. K.
  • mice Male Wistar rats weighing 200-230 gm were laparatomized under ether anesthesia; and 0.05 ml of 30% acetic acid solution was injected into the subserosal layer in the glandular stomach. Then the abdomen was closed and the rats were fed normally. CD1 or CD suspended in 0.5% C.M.C. solution was administered orally twice a day. The control animals were treated with the vehicle alone. The animals were sacrificed 15 days after said operation to observe the curative ratio of the ulcers, and the results are summarized below as examples and tables.
  • composition CD chosen in 88% of agent A and 12% of agent B is tested as an example under procedures of acetic acid ulcer mentioned above. And we obtained the results shown herebelow in Table I.
  • composition CD1 chosen in 68% of agent A, 9% of agent B and 23% of agent C is tested as an example under procedures of acetic acid ulcer mentioned above. We obtained the results shown herebelow in Table II.
  • CD1 has an excellent curative ratio in therapeutic effect on chronic peptic ulcer. Besides, it also has less side effects than other agents.

Abstract

An antipeptic ulcer composition comprising ferrous sulfate, clove, and licorice.

Description

This is a continuation, of application Ser. No. 854,549, filed Nov. 25, 1977, now abandoned.
The present invention relates to an antipeptic ulcer composition. More particularly, it provides an antipeptic ulcer composition comprising, ferrous sulfate, clove and optionally licorice herebelow referred as agents A, B and C, respectively.
The agent A, ferrous sulfate, is commonly known as a treatment for iron deficiency; the agent B, clove, is used as a carminative and a flavor; and the agent C, licorice, is considered to possess demulcent, expectorant and laxative properties and is used considerably as a flavoring agent.
In the recent years, the extracts of licorice with various solvents have been employed in treating peptic ulcer, such as carbenoxolone, glycyrrhetic acid (K2) and FM100. But the composition according to the present invention shows a great deal of difference from them. Besides, there has been no one using agent A or both A and B for antipeptic ulcer composition.
The present inventor has been carrying out research on various compositions of agents A, B and C. It is found no curative effect when merely use agents A and C. A composition using A and B, herebelow referred as CD, indeed has some curative effect. Most of all, a composition using A, B and C herebelow referred as CD1, shows excellent synergistic cooperative action in treating peptic ulcer. The mechanism in the curative action of said compositions CD or CD1 has not been clarified yet, but it seems to be very different from that of antacid or anticholinergic drug.
The curative test of CD1 as described below shows that CD1 is much more effective than antacid, antipeptic agent (carrageenin), and anticholinergic drug (atropine sulfate). The curative ratio of CD1 even exceeds that of the most effective drug FM100.
The antipeptic ulcer compositions of the present invention CD and CD1 are prepared by compounding agents A, B and A, B, C respectively. When compositions of the present invention are administered as antipeptic ulcer compositions, it is advantageous to administer them as tablets, powders capsules or granules. The pharmaceutically acceptable excipients which can be used for said purpose are corn starch, or starch paste.
The animal test procedures are like those in acetic acid ulcer (so-called intractible ulcer). The details of the experimental procedures can be obtained with reference to Jap. J. Pharmacology 19.418, 1969 by Takagi. K.
In the experiments according to the present invention, male Wistar rats weighing 200-230 gm were laparatomized under ether anesthesia; and 0.05 ml of 30% acetic acid solution was injected into the subserosal layer in the glandular stomach. Then the abdomen was closed and the rats were fed normally. CD1 or CD suspended in 0.5% C.M.C. solution was administered orally twice a day. The control animals were treated with the vehicle alone. The animals were sacrificed 15 days after said operation to observe the curative ratio of the ulcers, and the results are summarized below as examples and tables.
EXAMPLE I
A composition CD chosen in 88% of agent A and 12% of agent B is tested as an example under procedures of acetic acid ulcer mentioned above. And we obtained the results shown herebelow in Table I.
              TABLE I                                                     
______________________________________                                    
        Admin-   No.                                                      
        istration                                                         
                 of     Ulcer Index ±                                  
                                  Curative                                
                                         P                                
Treatment                                                                 
        time     rats   SE (mm.sup.2)                                     
                                  ratio  value                            
______________________________________                                    
Control 15 days  10     16.2 ± 1.6                                     
CD:80   15 days   7     12.6 ± 2.3                                     
                                  22.4%  >0.2                             
mg/kg                                                                     
FM 100:200                                                                
        15 days  10      9.5 ± 1.9                                     
                                  41.2%  <0.02                            
mg/kg                                                                     
______________________________________                                    
 Remarks: The ulcer index is defined as the sum of the ulcer area which wa
 calculated by multiplying the length by the width of each ulcer.         
EXAMPLE II
A composition CD1 chosen in 68% of agent A, 9% of agent B and 23% of agent C is tested as an example under procedures of acetic acid ulcer mentioned above. We obtained the results shown herebelow in Table II.
              TABLE II                                                    
______________________________________                                    
        Admin-   No                                                       
        istration                                                         
                 of     Ulcer Index ±                                  
                                  Curative                                
                                         P                                
Treatment                                                                 
        time     rats   SE (mm.sup.2)                                     
                                  ratio  value                            
______________________________________                                    
Control 15 days  7      21.7 ± 2.0                                     
CD1:100 15 days  7       9.6 ± 1.7                                     
                                  55.7%  <0.001                           
mg/kg                                                                     
______________________________________                                    
For the purpose of comparison and reference, the curative ratio of several conventional drugs by 15 days administration were as follows:
______________________________________                                    
                               Curative                                   
No.   Drugs                    ratio                                      
______________________________________                                    
1.    Aluminum silicate (1000 mg/kg per o.s.)                             
                               11.4%                                      
2.    Atropine Sulfate (20 mg/kg s.c.)                                    
                               26.7%                                      
3.    Chlorophyl Cu--Na (500 mg/kg per o.s.)                              
                               39.8%                                      
4.    Glycyrrhetic acid (K.sub.2) (700 mg/kg per o.s.)                    
                               33.7%                                      
______________________________________                                    
 Remarks: Data from Jap. J. Pharmacol. 19.418 (1969).                     
Besides, a seasonal variation of experimental results in FM100 are listed in Table III.
              TABLE III                                                   
______________________________________                                    
     Admin-                No.  Ulcer                                     
Exp. istration             of   Index ±                                
                                        Curative                          
No.  time     Treatment    rats SE (mm.sup.2)                             
                                        ratio                             
______________________________________                                    
1    10 days  Control      10   20.9 ± 3.7                             
                                        32%                               
              FM 100:400 mg/kg                                            
                           10   14.3 ± 2.0                             
2    10 days  Control      11   19.2 ± 2.6                             
                                        38%                               
              FM 100:200 mg/kg                                            
                           12   11.8 ± 1.4                             
3    10 days  Control      12   19.5 ± 3.1                             
                                        41%                               
              FM 100:200 mg/kg                                            
                           11   11.4 ± 1.9                             
4    10 days  Control       8   33.1 ± 4.3                             
              FM 100:200 mg/kg                                            
                           10   15.1 ± 1.6                             
                                        54%                               
              400 mg/kg    10   16.6 ± 2.6                             
                                        50%                               
5    15 days  Control      18   22.6 ± 4.0                             
                                        50%                               
              FM 100:400 mg/kg                                            
                           16   11.4 ± 2.6                             
______________________________________                                    
 Remarks: Data from Jap. J. Pharmacol. 21.832 (1971).                     
Therefore, it is concluded that CD1 has an excellent curative ratio in therapeutic effect on chronic peptic ulcer. Besides, it also has less side effects than other agents.

Claims (9)

What I claim is:
1. An orally administered antipeptic ulcer composition comprising a therapeutically effective amount of ferrous sulfate, clove and licorice.
2. The antipeptic ulcer composition of claim 1, in conjunction with a pharmaceutically acceptable carrier.
3. The antipeptic ulcer composition of claim 2, in the form of tablets or powders.
4. The antipeptic ulcer composition of claim 2, wherein the ratio of ferrous sulfate to clove is 68-88:4-12, respectively, by weight.
5. The antipeptic ulcer composition of claim 1, consisting of 68 weight % ferrous sulfate, 9 weight % clove and 23 weight % licorice.
6. A method for treating a peptic ulcer by orally administering a composition comprising a therapeutically effective amount of ferrous sulfate, clove and licorice.
7. The method of claim 6, wherein the ratio of ferrous sulfate to clove is 68-88:9-12, respectively, by weight.
8. The method of claim 6, wherein the composition consists of 68 weight % ferrous sulfate, 9 weight % clove and 23 weight % licorice.
9. The method of claim 6, wherein said composition is administered in conjunction with a pharmaceutically effective carrier.
US06/350,865 1976-11-30 1982-02-22 Antipeptic ulcer composition Expired - Fee Related US4544551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB49885/76A GB1548738A (en) 1976-11-30 1976-11-30 Antipeptic ulcer composition
GB49885/76 1976-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05854549 Continuation 1977-11-25

Publications (1)

Publication Number Publication Date
US4544551A true US4544551A (en) 1985-10-01

Family

ID=10453894

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/350,865 Expired - Fee Related US4544551A (en) 1976-11-30 1982-02-22 Antipeptic ulcer composition

Country Status (6)

Country Link
US (1) US4544551A (en)
DE (1) DE2753140C2 (en)
FR (1) FR2373286A1 (en)
GB (1) GB1548738A (en)
HK (1) HK47880A (en)
MY (1) MY8100157A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089583A1 (en) * 2003-10-28 2005-04-28 Rao Janaswamy M. Novel herbal composition for the treatment of gastric ulcer
CN107875197A (en) * 2016-09-30 2018-04-06 深圳市傲来大健康产业有限公司 A kind of composition and its production and use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"The Dispensatory of the United States of America", 25th Ed., J. B. Lippincott Company, Phila., pp. 337, 565, 619.
Soine et al., "Rogers' Inorganic Pharmaceutical Chemistry", pp. 616-619, Lea and Febiger (1961).
Soine et al., Rogers Inorganic Pharmaceutical Chemistry , pp. 616 619, Lea and Febiger (1961). *
The Dispensatory of the United States of America , 25th Ed., J. B. Lippincott Company, Phila., pp. 337, 565, 619. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089583A1 (en) * 2003-10-28 2005-04-28 Rao Janaswamy M. Novel herbal composition for the treatment of gastric ulcer
US7651705B2 (en) * 2003-10-28 2010-01-26 Council Of Scientific & Industrial Research Herbal composition for the treatment of gastric ulcer
CN107875197A (en) * 2016-09-30 2018-04-06 深圳市傲来大健康产业有限公司 A kind of composition and its production and use

Also Published As

Publication number Publication date
GB1548738A (en) 1979-07-18
FR2373286A1 (en) 1978-07-07
DE2753140C2 (en) 1985-01-03
FR2373286B1 (en) 1980-10-17
HK47880A (en) 1980-09-05
MY8100157A (en) 1981-12-31
DE2753140A1 (en) 1978-06-01

Similar Documents

Publication Publication Date Title
EP0391905B1 (en) Use of disaccharide polysulfate-aluminium compound in the manufacture of a medicament for treating HEMORRHOIDs and for wound healing
US5478814A (en) Hemorrhoidal, other compositions and methods of treatment
US4857554A (en) Method for the treatment of psoriasis
US4749572A (en) Pharmaceutical preparations
US4474813A (en) Pharmaceutical preparations comprising flutamide
RO108220B1 (en) Pharmaceutical preparates for muscular cramps struggling against and preparation process therefor
Cioli et al. Evaluation of the potential of gastric ulceration after administration of certain drugs
Derelanko et al. Carbenoxolone sodium protects rat gastric mucosa against ethanol-induced necrosis
Sontag Prostaglandins in peptic ulcer disease: an overview of current status and future directions
US4544551A (en) Antipeptic ulcer composition
JPS62298530A (en) Pharmaceutical composition for suppository
KR19990067237A (en) Pharmaceutical composition for treating autoimmune disease
JPS6213328B2 (en)
JPH01193224A (en) Pharmaceutical composition containing moxonidine and production thereof
DD209735A5 (en) METHOD FOR THE PRODUCTION OF A NEW MEDICAMENT PREPARATION
EP0624373B1 (en) Pharmaceutical preparation containing bismuth and amoxycillin and its use
DE19849737A1 (en) Combination agent for the treatment of inflammatory bowel disease
US4732760A (en) Curative and preventive agent for ulcers of digestive organs
DE2554902A1 (en) NEW COMBINATIONS OF MEDICINAL PRODUCTS AND PROCESSES FOR THEIR MANUFACTURING
CN105878263B (en) Pharmaceutical composition containing Amicos (Banyu) and its application
US4447437A (en) Pharmaceutical composition and method for treatment of peptic ulcer
US3108041A (en) Antitussive compositions
JPH0395114A (en) Therapeutic medicine for peptic ulcer at stomach and duodenum
US2990327A (en) Composition and method for treating biliary dyskinesia
CN105853419B (en) A kind of pharmaceutical composition and its application for gastric ulcer treatment

Legal Events

Date Code Title Description
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19971001

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362